1 **NK cell immune responses differ after prime and boost vaccination**

2 Jean-Louis Palgen^{1,2}, Nicolas Tchitchek^{1,2}, Nicolas Huot^{2,3}, Jamila Elhmouzi-Younes^{1,2}, Cécile
3 Lefebvre^{2,4}, Pierre Rosenbaum^{1,2}, Nathalie Dereuddre-Bosquet^{1,2}, Frédéric Martinon^{1,2}, Hakim
4 Hocini^{2,4}, Antonio Cosma^{1,2}, Michaela Müller-Trutwin^{2,3}, Yves Lévy^{2,4}, Roger Le Grand^{1,2}, and
5 Anne-Sophie Beignon^{1,2,*}

6

7 ¹ CEA – Université Paris Sud 11 – INSERM U1184, Immunology of Viral Infections and
8 Autoimmune Diseases, IDMIT department, IBFJ, 92265 Fontenay-aux-Roses, France

9 ² Vaccine Research Institute, Henri Mondor Hospital, 94010 Créteil, France

10 ³ Institut Pasteur, Unit on HIV, Inflammation and Persistence, 75015 Paris, France

11 ⁴ Institut Mondor de Recherche Biomédicale – INSERM U955, Eq.16, 94010, Créteil, France

12 *Corresponding author: Anne-Sophie Beignon; 18, route du Panorama; 92265 Fontenay-aux-
13 Roses, France; Phone: +33 1 46 54 80 27; Fax : +33 1 46 54 77 26; email: anne-
14 sophie.beignon@cea.fr

15

16

17

18

19 Short title: NK cell response after immunizations

20 **Abbreviations:**

21 CBC: complete blood count

22 DC: dendritic cell

23 HIV: human immunodeficiency virus

24 LASSO: Least Absolute Shrinkage and Selection Operator

25 LDA: Linear Discriminant Analysis

26 MCMV: mouse cytomegalovirus

27 MSI: mean signal intensity

28 MVA: modified vaccinia virus Ankara

29 NHP: nonhuman primates

30 NK: natural killer

31 PBMC: peripheral blood mononuclear cell

32 SPADE: Spanning-tree Progression Analyses of Density-normalized Events

33

34 **Abstract**

35 A better understanding of innate responses induced by vaccination is critical for designing
36 optimal vaccines. Here, we studied the diversity and dynamics of the NK cell compartment
37 after prime-boost immunization with the modified vaccinia virus Ankara using cynomolgus
38 macaques as a model. Mass cytometry was used to deeply characterize blood NK cells. The NK
39 cell subphenotype composition was modified by the prime. Certain phenotypic changes
40 induced by the prime were maintained over time and, as a result, the NK cell composition
41 prior to boost differed from that before prime. The key phenotypic signature that
42 distinguished NK cells responding to the boost from those responding to the prime included
43 stronger expression of several cytotoxic, homing, and adhesion molecules, suggesting that NK
44 cells at recall were functionally distinct. Our data reveal potential priming or imprinting of NK
45 cells after the first vaccine injection. This study provides novel insights into prime-boost
46 vaccination protocols that could be used to optimize future vaccines.

47

48 **Keywords:** innate lymphoid immunity, NK cells, prime-boost, vaccination, MVA, NHP, mass
49 cytometry, transcriptomics.

50 **Introduction**

51 A better understanding of the early events following vaccination is critical for identifying key
52 biomarkers and mechanisms involved in the subsequent establishment of immune memory
53 to optimize future vaccines (1). This requires extensive characterization of the vaccine-
54 induced innate immune response.

55 Natural Killer (NK) cells are innate lymphoid cells that can constitutively kill cells carrying an
56 abnormal MHC signature, via interactions of activating and inhibitory receptors between NK
57 cells and their targets (2–4). The wide diversity of the NK cell receptor repertoire implies a
58 large range of potential NK cell subpopulations (5). NK cells exhibit numerous functions other
59 than cytotoxicity, including modulation of the behavior of other innate and adaptive immune
60 cell populations, such as through cross-talk with dendritic cells (DCs) or cytokine production
61 (6–10). In particular, NK cells strongly interact with DCs, resulting in the activation of both cell
62 types (11,12). Also, NK cells were shown to orientate the B cell response and the underlying
63 affinity maturation via the restriction of follicular helper T cells, a feature that is key in the
64 generation of broadly neutralizing antibodies (13). NK cell functions are influenced by
65 vaccination and infection (14,15). In addition, recent findings in mice, macaques, and humans
66 indicate that NK cells show adaptive-like features (16–19). However, it is not yet fully clear
67 how these findings can be exploited to improve the immunogenicity and protective efficacy
68 of vaccines (20,21). More studies on vaccine-induced NK cell immunity are thus admittedly
69 required for improving vaccine design.

70 Modified vaccinia virus Ankara (MVA) is an attenuated vaccine derived from vaccinia virus,
71 first developed as a vaccine against smallpox, which now serves as the vector for many
72 recombinant vaccine candidates because of its capacity to induce strong and long-lasting

immunity (22). MVA is known to activate NK cells in mouse bone marrow and spleen, where it induces NK cell proliferation (23), as well as in lymph nodes, where NK cells accumulate via CXCR3 signaling after being sensed by macrophages. Such recruitment is crucial for the induction of Th1 responses (24). Moreover, the vaccine we used (MVA HIV B) was reported to prime human NK cells via NK-DC crosstalk *in vitro* (25). Other studies in mice reported that NK cells are recruited to tissues in response to MVA-induced CCL2 (MCP-1) expression by macrophages (26). We previously reported a difference in the level of CCL2 in the blood of macaques after an MVA boost relative to prime (27). These and other studies show that MVA modulates NK cell activity and trafficking. They moreover suggest an important contribution of NK cells to MVA-induced immunity.

Nonhuman primates (NHP) are an important animal model in vaccinology, given their close immune proximity with humans, including innate immunity (28). Immune responses in macaques to human vaccine injection are highly predictive of vaccine immunogenicity in humans. This is particularly true for MVA (29). Human NK cells are usually subdivided based on CD56 and CD16 expression, whereas most NK cells from macaques are CD8 α ⁺ CD56⁻ (30). In addition, both human and macaque NK cells express NKp46, but in macaques NKp46 may not be expressed by all NK cell subpopulations (28,31). Nevertheless, close phenotypic analogies have been found between macaque and human NK cell subpopulations and functional studies have revealed similar behavior in both species (32–35).

We previously uncovered the phenotypic complexity and diversity of innate myeloid cells in the blood and the impact of vaccinations on the dynamics of their subset composition by mass cytometry (27) in cynomolgus macaques immunized with a recombinant MVA HIV-B. We used the very same animals and a similar analytical workflow, but a 31-marker mass cytometry

96 antibody panel dedicated to the analysis of NK cells, to determine the phenotype of blood NK
97 cell subpopulations, as well as their diversity and evolution throughout the vaccination
98 process.

99 We demonstrated a high phenotypic diversity within the blood NK cell compartment in
100 macaques. Importantly, the study reveals the induction of changes within the NK cell
101 subphenotype composition by the prime, some of which were maintained over time. Hence,
102 the NK cells present at recall were different from those present at baseline. The key
103 phenotypic signature discriminating NK cells responding to boost from those responding to
104 prime was identified and included stronger expression of several cytotoxic, homing, and
105 adhesion molecules.

106 This study has important implications for understanding the role of NK cells in vaccine-induced
107 responses, as well as for the optimization of vaccine protocols.

108 **Material and Methods**

109 **Ethics statement**

110 The experimental protocols were approved by the ethics committee «Comité d'éthique en
111 expérimentation animale n°44 » under the reference 2015031314518254.02 (APAFIS#319) for
112 the longitudinal analysis of the MVA-induced response, and 2015062215324227v1
113 (APAFIS#891) when comparing MVA and buffer injections, and the «Ministère de l'Education
114 Nationale, de l'Enseignement Supérieur et de la Recherche» (France). Animals were handled
115 by veterinary staff in accordance with national regulations (CEA Permit Number A 92-32-02)
116 and the European Directive (2010/63, recommendation N°9) and in compliance with the
117 Standards for the Humane Care and Use of Laboratory Animals of the Office for Laboratory
118 Animal Welfare (OLAW, USA) under OLAW Assurance number #A5826-01.

119

120 **Experimental design**

121 Five male adult cynomolgus macaques, originating from Mauritius and identified as BB078,
122 BB231, BC641, BD619, and BD620, were housed individually. Before inclusion in the study,
123 they were tested to be negative for SIV, herpesvirus B, filovirus, STLV-1, SRV-1, SRV-2, measles
124 virus, Hepatitis B antigen, and antibodies. Regarding CMV, BB078, BB231, and BC641 were
125 seropositive, whereas BD620 was seronegative. Animals were captive-born (first generation,
126 F1), 7-8 year old and weighed 8.2-10.7 kg at the beginning of the study.

127 Without prior selection, unbiased distribution of MHC haplotype was observed in our group of animals,
128 with animals carrying one of the complete seven common haplotypes (with H1, H2, and H3 being the
129 most common), or recombinants, and none of them being homozygous, or matching with one another
130 for an entire MHC haplotype.

Animals were inoculated subcutaneously with 4×10^8 PFU of the ANRS MVA HIV-B vaccine (MVATG17401; Transgene, Illkirch-Graffenstaden, France) (36), encoding HIV-Gag (amino-acids 1-519), Pol (amino-acids 172-219, 325-383 and 461-519), and Nef (amino-acids 66-147 and 182-206) proteins, as previously described (27,37). Animals were immunized two months apart following a homologous prime-boost strategy.

For comparison of buffer and MVA injection, six macaques received a subcutaneous injection with a buffer containing 10 mM Tris-HCl, saccharose 5% (w/v), 10 mM NaGlu, 50 mM NaCl, pH8.0. One month later they were inoculated with 4×10^8 PFU of the ANRS MVA HIV-B vaccine. Animals were 2-5 year old and weighed 4.9 to 6.7 kg. Without prior selection, unbiased distribution of MHC haplotype was observed in this control group of animals, with some animals carrying one of the complete seven common haplotypes or recombinants, and none of them being homozygous or matching with one another for an entire MHC haplotype.

Blood was collected in EDTA tubes for complete blood count and whole blood flow cytometry, lithium heparin tubes for whole blood mass cytometry analysis, and heparin cell preparation tube (CPT) (Becton Dickinson, Franklin Lakes, USA) for peripheral blood mononuclear cell (PBMC) isolation.

Sample preparation

Fixed leukocytes were prepared for mass cytometry using a previously described cell fixation protocol (27,38,39), which allows the recovery of all leukocytes, including granulocytes, from lithium-heparin whole blood. Briefly, 1 mL of blood was incubated with a fixation buffer containing formaldehyde and glycerol for 10 min at 4°C. After centrifugation, erythrocytes were lysed in 10 mL milli-Q water at room temperature for 20 min. Cells were then washed in

1X DPBS and stored at -80°C at a final concentration of 15×10^6 cells/mL in the fixation mixture.

Note that cells were fixed extemporaneously without re-stimulation *ex vivo*.

PBMCs were prepared for transcriptome analysis. Blood was collected using CPT tubes. After centrifugation at $1,200 \times g$ for 30 min at RT, PBMCs were isolated, and remaining contaminating red blood cells, if any, were lysed with ACK lysis buffer (Thermo Fisher Scientific, Waltham, USA). PBMCs were then washed in complete culture medium composed of RPMI 1640 (Invitrogen, Carlsbad, USA) supplemented with 10% heat-inactivated FCS (Eurobio, Courtaboeuf, France) and 1% Penicillin-Streptomycin/Neomycin (Thermo Fisher Scientific, Waltham, USA).

Cell staining and acquisition

Fixed leukocyte staining and acquisition protocols were identical to those previously described (27). The 31-marker antibody panel used in the present study is described in **Table 1**. A number of classical NK cell receptors and other markers of interest (6,40) could not be included at the time of the study due to lack of reactivity of the tested antibody clones with fixed macaque leukocytes (CD27: clones O323 and LG-7F9; NKp80: clones 4A4.D10 and 5D12; NKp30: clone AF29-4D12; CD117: clone 104D2; NKp46: clone BAB281; CX3CR1: clone 2A9-1; CXCR3: clone 1C6; CD122: clone Tu27; CD158a: clone HP-3E4; and CD161: clone DX12).

Data processing and event selection

FCS files were normalized with the MATLAB normalizer from Rachel Finck *et al.* (41). Replicates were concatenated using the tool from Cytobank (Mountain View, USA). Leukocytes were

gated based on event length, iridium content, and exclusion of non-specifically stained CD66⁺CD3⁺ eosinophils (27,39).

Complete blood count and cell population count

Complete blood counts (CBCs) were performed using blood collected in EDTA with the HmX instrument (Beckman Coulter). The absolute number of cells in each sample for a given cell population was computed as follows: $N = \text{the absolute number of leukocytes (expressed per } \mu\text{L of blood)} \times \text{the number of cells in the population detected by CyTOF} / \text{total number of leukocytes (excluding CD3}^+\text{CD66}^+ \text{ cells) detected by CyTOF}$ (given in **Table 2**).

Identification of cell populations

The Spanning-tree Progression Analyses of Density-normalized Events (SPADE) (42) algorithm was performed on the whole dataset of samples from macaques BB078, BB231, BC641 and BD620 to automatically identify cell populations displaying similar expression levels for the given markers used for clustering: CD66abce, HLA-DR, CD3, CD107a, CD8, CD45, granzyme B, CD56, CD62L, CD4, CD11a, CD2, CD7, NKG2D, CD11c, CD69, CD25, CD16, CCR5, CXCR4, CD14, perforin, NKG2A/C, CD20, and CCR7. Prior to clustering, we performed random pre-downsampling of 50,000 cells (corresponding to the highest number of cells contained in all samples) to avoid bias in the analysis towards samples with more cells than others (**Table 2**). The quality of the SPADE clustering, defined as a narrow and unimodal distribution for each marker in all cell clusters and NK cell clusters was assessed using the SPADEVizR R package we developed (43).

198 Based on these quality control measurements, SPADE was parameterized to identify 900
199 clusters using a downsampling of 20%, leading to 77.44% of all clusters with unimodal
200 (Hartigan's dip test, $p\text{-value} \leq 0.05$) and narrow distribution ($\text{IQR} \leq 2$) of all markers. Most of
201 the non-unimodal distribution was attributable to perforin (154 clusters of 900 (17.11%)).

202 Among NK cell clusters identified on the SPADE tree, based on CD3 and CD8 expression,
203 66.67% (22 of 33) had a unimodal and narrow distribution for all markers. Non-unimodal or
204 wide distribution was not associated with a particular marker; at worst CD2 and CD16
205 expression were non-unimodal or wide for 4 of 33 clusters (12.12%) (**Table 3**).

206 Two sets of baseline samples were available: 19 days before the prime (BPD19) and just before
207 the prime, coded 0 hour post-prime (HOPP) in our nomenclature. Only BPD19 samples
208 (available for the four macaques) were used for SPADE analysis to avoid biasing the SPADE
209 analysis toward baseline samples, since NK cells were more numerous before than early after
210 immunization. HOPP samples (only available for three of four animals) were upsampled into
211 the SPADE analysis, using the closest neighborhood method. Briefly, cells from HOPP samples
212 were assigned to the cluster of its closest cell-neighbor within the SPADE analysis. The
213 neighborhood definition was based on the SPADE clustering markers. The closest neighbors
214 were found using the FNN R package (available at <https://CRAN.R-project.org/package=FNN>)
215 and the kd-tree approach.

216 Samples from macaque BD619 were not included in this SPADE analysis since only H3PP, H6PP,
217 D1PP, and D1PB samples were available. Indeed, samples from this animal would have been
218 underrepresented among the samples from the other animals, and they could have biased the
219 clustering analysis towards early modification of the NK subphenotype composition.
220 Nevertheless, BD619 samples were mapped afterwards onto the SPADE tree for phenotypic

characterization based on the same closest neighbor approach used to map HOPP baseline samples.

We directly identified blood NK cells on the SPADE tree based on CD3 and CD8 expression, rather than by manual gating followed by SPADE analysis of the NK cells to avoid a bias in the manual gating of CD3⁻ CD8⁺ events and contamination with CD66^{low} neutrophils, which displayed a low background signal in all channels including CD8.

Categorical heatmap representation of NK cell clusters phenotypes

The median expression among all samples was used to generate the categorical heatmap using SPADEVizR (43). The range of marker expression was divided into five categories between the 5th and the 95th percentiles to define the cell cluster phenotype. Samples containing less than 10 cells were removed from the median computation. Hierarchical clustering, represented by the cluster and marker dendrograms in the heatmap, was performed using the Euclidean metric and the ward.D linkage method. The cluster dendrogram was used to define phenotypic families.

LASSO-LDA model to classify post-prime and post-boost NK cell immune profiles

The classification of post-prime and post-boost NK cell immune profiles was performed using a combination of the Least Absolute Shrinkage and Selection Operator (LASSO) and Linear Discriminant Analysis (LDA) methods. The LASSO method was based on the lars R package (available at <https://CRAN.R-project.org/package=lars>). Abundance profiles of phenotypic families were centered and reduced. Model validity was assessed through the leave-one-out

cross-validation method. The best configuration was chosen using the elbow criterion. Essentially, the minimum number of phenotypic families was chosen such that adding more phenotypic families did not improve the model. Graphically, this corresponds to the number of phenotypic families for which a break in slope (an “elbow”) is observed when plotting the mean square error of the model as a function of the number of phenotypic families used (Figure S5B). The LDA method was based on the MASS R package (available at <https://CRAN.R-project.org/package=MASS>). Marker expression density distributions were compared using the CytoCompare R package (44) based on the Kolmogorov-Smirnov distance.

Validation of the LASSO-LDA model

The LASSO-LDA classifier generated using BB078, BB231, BC641, and BD620 samples was used to classify BD619 samples and validate the model. Cell cluster abundances from BD619 samples were centered and reduced with the abundance of the four other animals.

RNA extraction and gene expression profiling

PBMCs were cultured overnight at 2.5×10^6 PBMCs/well in U-bottom 96-well plates (BD Falcon) in duplicate. PBMCs were recovered and lysed in 350 μ L of RLT Plus buffer (Qiagen, Hilden Germany) with 1% of mercaptoethanol. RNA was then purified using the RNeasy Plus Micro Kit (Qiagen, Hilden Germany). Purified RNA was quantified using an ND-8000 spectrophotometer (NanoDrop Technologies, Fisher Scientific, Illkirch, France) and the integrity verified on a 2100 BioAnalyzer (Agilent Technologies, Massy, France). cDNA was synthesized and biotin-labeled using Ambion Illumina TotalPrep RNA Amplification kits

(Applied Biosystem/Ambion, Saint-Aubin, France). Labeled cRNA was hybridized to Illumina Human HT-12V4 BeadChips, previously successfully used to analyze cynomolgus macaque whole genome (45,46). All steps were performed following the manufacturers' protocols.

Transcriptomic analysis

Transcriptomic signals were background corrected and quantile-normalized using the limma R package (available at <https://bioconductor.org/packages/release/bioc/html/limma.html>).

We identified genes associated with NK cell abundance (which is relatively low among PBMCs) by performing a two-step analysis approach. First, genes for which the expression correlated with total NK cell abundance (Pearson correlation, $|R| \geq 0.65$ and $p \leq 0.05$) were analyzed using the STRING database (47) to define interaction networks.

Transcriptomic data were expressed as fluorescence intensity (resulting from DNA probe hybridization) per 2.5×10^6 PBMCs. The percentage of NK cells among PBMCs was used for the correlation between transcript expressions and NK cell abundances. The number of PBMC in each leukocyte sample was estimated in our mass cytometry analysis by excluding CD66⁺ cells. Thus, the percentage of NK cells among PBMCs was defined as the number of CD3⁺ CD8⁺ NK cells detected in the CyTOF analysis divided by the number of CD66⁺ leukocytes identified in the CyTOF analysis multiplied by 100. The Pearson coefficient of correlation was used to quantify the association based on log-transformed data. The transcriptomic timepoint D57PP was associated with the mass cytometry timepoint H0PB (corresponding to D58PP). In addition, early transcriptomic timepoints (H3, H6, D1) were missing for both immunizations. The transcriptomic timepoints used were: D-19PP, D3PP, D57PP, and D3PB.

Second, genes having interactions with at least one other gene were selected, and a functional enrichment analysis was performed using Ingenuity Pathways Analysis software (Ingenuity Systems, Inc, IPA, Redwood City, USA) to further decipher the gene signature. IPA maps each gene identifier to its corresponding molecule in the Ingenuity Pathways Knowledge Base (IPKB). For all analyses, p-values generated by Fisher's exact test were adjusted by Benjamini-Hochberg Multiple Testing.

Correlation between NK cell and innate myeloid cell dynamics

The Spearman correlation coefficient between the abundance (number of cells per mL) of blood NK cell phenotypic families and the abundance of blood innate myeloid cell kinetic families (groups of phenotypic families sharing similar dynamics as previously defined (27)) was computed. The correlation was considered significant when $|R| \geq 0.6$ and $p \leq 0.05$.

Area under the curve

Areas under the curve (AUC) were calculated as the cumulative sum of concentrations of the population between H0 and D3 (either after prime or after boost). Post-prime and post-boost AUC were compared using the permutation test from the exactRankTests R package (available at <https://cran.r-project.org/web/packages/exactRankTests/index.html>).

Inter-individual variability

The inter-individual variability in term of phenotypic composition was quantified as the percentage of NK cells that are not classified in the same phenotypic families between two animals.

Flow cytometry

Flow cytometry staining was used to identify NK cells in a control group of 6 macaques used to assess whether the effect of immunizations on NK cell number was specific of MVA subcutaneous injection or could be induced by the sole buffer subcutaneous injection or no injection (only anesthetic). For each sample, 100µL of blood were stained during 30 minutes with 90µL of mix of antibodies diluted in BD Horizon® stained buffer (BD Biosciences, Franklin Lakes, USA) containing CD123 (BD Biosciences, Franklin Lakes, USA, Clone 7G3), HLA-DR (BD Biosciences, Franklin Lakes, USA, clone G46-6), CD163 (BD Biosciences, Franklin Lakes, USA, clone GHI/61), CD11c (Biolegend, San Diego, CA, USA clone 3.9), CD45 (BD Biosciences, Franklin Lakes, USA, clone DO58-1283), CD66 (Miltenyi Biotec, Bergisch Gladbach, Germany, clone TET2), CD3 (BD Biosciences, Franklin Lakes, USA, clone SP34-2), CD20 (BD Biosciences, Franklin Lakes, USA, clone 2H7), CD8 (BD Biosciences, Franklin Lakes, USA, clone RPA-T8), CD11b (Beckman Coulter, Brea, USA, clone Bear 1), CD14 (BD Biosciences, Franklin Lakes, USA, Clone M5E2), CD33 (Miltenyi Biotec, Bergisch Gladbach, Germany, Clone AC104.3E3), CD16 (Beckman Coulter, Brea, USA, 3G8) and NKG2A (Beckman Coulter, Brea, USA, clone Z199), and then cells were fixed and red blood cells were removed with 1 mL of BD FACs Lysing® (BD Biosciences, Franklin Lakes, USA) during 10 minutes at room temperature and washed twice using PBS. Samples were acquired with a BD LSR Fortessa (BD Biosciences, Franklin Lakes, USA).

330 NK cells were gated as CD66⁻ CD3⁻ CD20⁻ CD14⁻ CD8⁺ cells using FlowJo 9 software (FlowJo,
331 Ashland, USA). The absolute count numbers were calculated as the percentage of NK cells
332 among all cells X leukocyte count (CBC).

333

334 **Data availability**

335 Gated cytometry profiles are available on the FlowRepository database (48) under accession
336 number FR-FCM-ZYPY. Raw transcriptomic profiles are available on the EBI-ArrayExpress
337 database (49) under accession number E-MTAB-7697. Main graphical representations and
338 statistical results are available in an interactive format on the IDMIT data dissemination
339 platform accessible at <http://data.idmitcenter.fr/MVA-innate-NK/>.

340

Results

Total NK cell kinetics do not differ between prime and boost

We vaccinated four adult male cynomolgus macaques with a recombinant MVA-based vaccine following the homologous prime-boost strategy described in **Figure 1A** (27,37). Blood samples were taken before and at various timepoints during the vaccination time course and fixed extemporaneously without *ex vivo* re-stimulation with the vaccine. All samples were stained with the antibody panel targeting markers of NK cell activation (*e.g.*, CD25 and CD69), function (*e.g.*, IFN γ , perforin, granzyme B, CD107a, and CD11a), and maturation (*e.g.*, CD2, CD7, and CXCR4), described in **Figure 1B** and detailed in **Table 2**. We then followed the analysis pipeline described in **Figure 1C**. Preliminary analyses showed high inter-individual variability in terms of NKG2A/C expression among NK cells, not associated with CMV serology (**Figure S1**).

First, we performed a SPADE analysis to identify cell populations based on the expression of the following markers: CD66abce, HLA-DR, CD3, CD107a, CD8, CD45, granzyme B, CD56, CD62L, CD4, CD11a, CD2, CD7, NKG2D, CD11c, CD69, CD25, CD16, CCR5, CXCR4, CD14, perforin, NKG2A/C, CD20, and CCR7. This strategy allowed the segregation of NK cells, defined classically for macaques as CD3⁻ CD8⁺ cells, from other leukocytes and into 33 cell clusters on a separate branch of the SPADE tree (**Figure 2A**). Note that we notably excluded CD66⁺ neutrophils, HLA-DR⁺ CD14⁺ monocytes, HLA-DR⁺ CD11c⁺ cDCs, CD3⁺ T cells, and HLA-DR⁺ CD20⁺ B cells (**Figure S2**).

We analyzed the kinetics of all NK cell clusters in the blood throughout vaccination (**Figure 2B**). As expected, the number of total NK cells in the blood was relatively low (< 0.5x10⁶cells/mL for all timepoints). NK cell numbers were homogeneously affected by immunization in all animals. Indeed, NK cell numbers tended to decrease between 3 h (H3)

and 6 h/1 day (H6-D1) post-immunization, both post-prime (PP) and post-boost (PB). These changes in NK cell counts were likely to be MVA injection-specific, as shown by six additional control animals (**Figure S3**). A high variability in term of NK cell count was observed between baselines (untreated animals, before buffer injection, and before MVA injection) across the control animals (**Figure S3A**). Buffer injection did not induce a significant early decrease in total NK cell count ($p=0.9839$) (**Figure S3B**), whereas MVA injection did ($p=0.03697$) (**Figure S3C**).

This MVA-induced decrease in NK cell count likely corresponds to NK cell recruitment to either inflamed tissues or lymphoid organs, consistent with a previous study in mice describing the recruitment of NK cells to the draining lymph node within the first day after MVA injection (24). There were no significant differences in the NK cell dynamics between the two immunizations based on the comparison of post-prime and post-boost areas under the curves.

To further complete the picture of the NK cell response at the whole compartment level, we analyzed the gene signature associated with NK cell number using microarrays on isolated PBMCs (**Figure 3A**). There were numerous genes for which the expression correlated with NK cell abundance with a remarkably high number of gene interactions, among them, a cluster of NK cell-associated genes, such as activation/cytotoxic associated molecules (CD226, CD69, KLRK1 (NKG2D), granzyme B, and granzyme H) (50–53), as well as genes encoding proteins involved in these signaling pathways (notably ITGAL/CD11a and VAV3) (54) and the chemoattractant cytokine CCL27 (55).

Functional enrichment of this interacting network of genes confirmed a strong association with NK cells, which indicated that we were able to find an NK cell-associated signature within the PBMCs. More specifically, this gene signature was associated with NK cell/DC crosstalk,

NK cell cytotoxic activity, and FcR-mediated phagocytosis. To a lesser extent, this signature was associated with granulocyte diapedesis (a surprising signature, as only PBMC RNA was used) and fatty acid oxidation (**Figure 3B**). Among regulators, the most statistically significant was the IL-12 complex (**Figure 3C**), which is a well-known key cytokine in NK cell biology (56). ESR1, LCK, CD46, and ITGAL/CD11a were also found to be engaged. ESR1, LCK, and ITGAL/CD11a are associated with NK cell cytotoxic activity (54,57–59), whereas CD46 is associated with complement activity (60).

We previously showed, with the very same animals that IL-12 production was upregulated in blood neutrophils responding to the second MVA injection, as compared to those responding to the first MVA inoculation. IL-12 concentration in plasma did not differ between prime and boost though. (27). Thus, since no significant difference was found at the level of total NK cell number by contrast to IL-12 level in neutrophils, and since IL-12 signaling appeared correlated with NK cell number in blood, we further investigated whether differences could exist at a deeper phenotypic resolution of the NK cell compartment.

The NK cell compartment displays numerous subphenotypes

We used high-dimensional analysis based on marker expression intensity to investigate potential changes in NK cell phenotype after immunization. The double clustering of markers and NK cell clusters resulted in a categorical heatmap with a marker and cell cluster dendrogram. It facilitated the visualization of the phenotypes of all NK cell clusters at a glance (**Figure 4**). On this heatmap, marker expression was divided into five bins between the 5th and 95th percentile of the distribution across the whole dataset. This allowed us to qualify the

410 expression of each marker for each cluster as very low, low, mid, high or very high, according
411 to the bin in which the cluster fell for the indicated marker.

412 The hierarchical clustering of markers represented in the marker dendrogram revealed two
413 large groups of co-expressed markers, further subdivided into four subgroups (**Figure 4**). One
414 large group of co-expressed markers contained cytotoxic and maturation markers and
415 comprised highly co-expressed markers among most NK cells (granzyme B, CD107a, NKG2A/C,
416 CD8, CD7, CD45, and CD11a) in a first subgroup and highly/moderately co-expressed markers
417 (perforin, NKG2D, CD16, CD2, CCR5, CD56, and CXCR4) in a second. The second large group
418 contained, notably, several cytokine and chemokine receptors and consisted of
419 moderately/weakly co-expressed markers (IL-10, Ki-67, MIP-1 β , IL-4, TNF α , CD20, CD69, and
420 CD11c) in a first subgroup and weakly/unexpressed markers (CD14, CD4, HLA-DR, CD25,
421 CD62L, IFN γ , CCR7, CD66, and CD3) in a second.

422 The hierarchical clustering of NK cell clusters, represented in the cluster dendrogram, revealed
423 10 phenotypic NK cell families, arbitrarily numbered from 1 to 10, distributed within three
424 superfamilies, named A to C (**Figure 4**). Each phenotypic family contained NK cell clusters with
425 similar phenotypes, and each superfamily was composed of proximal phenotypic families.
426 Phenotypic families are likely to better correspond to biologically meaningful cell populations
427 than cell clusters. Indeed, the number of leukocyte clusters chosen as an entry parameter in
428 our SPADE analysis (900 cell clusters) was optimally defined to achieve a uniform and narrow
429 expression of all clustering markers in a maximum number of leukocyte clusters. Admittedly,
430 it could have resulted in a potentially artificially high number of NK cell clusters (33 NK cell
431 clusters). The risk of over-clustering was overcome by merging phenotypically similar NK cell
432 clusters into phenotypic families.

Superfamily A (phenotypic families 5, 3, 8, and 1) consisted of NKG2D^{high} CD16^{high} CD107a^{high} CCR5^{high} NK cells. Superfamily B (phenotypic families 4, 2, and 6) consisted of NKG2D^{mid} CD16^{mid} CD107a^{high} CCR5^{mid} NK cells. Finally, superfamily C (phenotypic families 10, 7, and 9) contained NKG2D^{low} CD16^{low} CD107a^{mid} CCR5^{low} NK cells.

Beyond such wide phenotypic NK cell diversity, which underlined varying degrees of expression of cytotoxicity markers and likely past, ongoing or future cytotoxicity, two phenotypic families (phenotypic families 1 and 4) in superfamilies A and B were CD2^{high}, suggesting higher activation ability towards antibody coated pathogen/antigen binding. CD2 is a well-known NK cell activator (61), which was shown to potentiate the CD16 signaling cascade *in vivo* in humans (62). This action was later shown to be associated with CD58 engagement on infected cells by CD2⁺ NK cells *in vitro* (63). Also, phenotypic family 9, within superfamily C, was the only one to be CD7^{mid} (all other NK clusters were CD7^{high}), likely related to a lower maturity. Indeed CD7 has been shown to be expressed on highly differentiated cytotoxic and cytokine-producing NK cells *ex vivo* in humans (64). Moreover, two phenotypic families containing one single cluster displayed very peculiar phenotypes (**Figure S4**). Phenotypic family 8, was CD66^{high}, whereas other NK cell clusters were CD66^{low/-}, as expected. It may consist of activated NK cells that can be inhibited through CD66, as reported after homotypic CD66a interactions between melanoma and NK cells (65). Phenotypic family 10 was HLA-DR^{high} granzyme B^{low} CD107a^{low} and may correspond to “NK DCs” observed in mouse tissues (66) and *ex vivo* in humans (67).

NK cell subphenotypes exhibit different kinetics

We then studied the dynamics of all identified NK cell phenotypic families (**Figure 5A**), which, for some, contrasted with those of total NK cells (**Figure 2B**). We identified distinct and complex patterns.

The phenotypic family 7 was more highly affected by the prime than the boost (AUC comparison, $p=0.0286$).

By contrast, two phenotypic families (3 and 8) were more highly affected by the boost than the prime (AUC comparison, $p=0.057$ and 0.0286 , respectively). In particular, family 3 showed a strong increase at H3PB compared to H3PP ($p=0.0286$).

The remaining seven phenotypic families (1, 2, 4, 5, 6, 9 and 10) displayed strong inter-individual variability in their dynamics and various patterns. Phenotypic family 10 notably only showed a very low peak at D14PP. Still note that for phenotypic family 5, 3 animals out of 4 showed a stronger increase in number post-prime than post-boost.

Although the number of total NK cells was low throughout vaccination and essentially transiently decreased (**Figure 2B**), many NK cell subphenotypes (*e.g.*, phenotypic families 7, 3, 5, 1, and 9) conversely showed an increase in absolute number for some timepoints (**Figure 5A**).

We then determined the relative abundance of the phenotypic families within each animal for each timepoint (**Figure 5B**). There was high inter-individual diversity of the NK cell compartment relative to that of the innate myeloid cell compartment (27). In addition, NK cell number and composition strongly differed between both baseline samples at D-19PP and HOPP, in the absence of any other experimental perturbation of the immune system (**Figure S5**). At baseline, prior to any immunization, there was high intra-individual variability in terms of cell number, with a difference of up to 0.8×10^6 NK cells/mL of blood between D19PP and

HOPP(**Figure S5**). This is fully consistent with the results obtained on the six additional control animals (**Figure S3A**). To note, the phenotypic composition was remarkably stable within each animal between the two baselines (**Figure S5**).

Note that prior to any immunization a high inter-individual variability was observed in term of the phenotypic composition of the NK cell compartment. Actually, on average $50 \pm 6\%$ of the NK cell compartment differ phenotypically between two animals (*i.e.*, $50 \pm 6\%$ of NK cells were associated with distinct phenotypic families between two animals). Strikingly, the phenotypic composition of the NK cell compartment after immunization was far more similar between the different animals ($32 \pm 6\%$ of difference between individuals at every other timepoint), indicating that immunization homogenizes the NK cell compartment composition.

The distribution of NK cell subphenotypes changed markedly throughout the prime, as early as H3PP, and dramatically between H6PP and D1PP. The major shift in the composition of the NK cell compartment remained relatively stable up to D14 (**Figure 5B**). Further changes of the subphenotype composition occurred later, between D14PP and the boost (at D58PP = H0PB). This was not observed for innate myeloid cells, for which the shift occurred essentially between D14PP and the boost (27). One explanation is that these subphenotypes correspond to newly generated immature NK cells arising from the bone marrow, whereas all NK cells expressing homing markers, such as CCR5, CCR7, CD62L, and CXCR4 (which is indeed the case for families 3, 5, and 8, which decreased in frequencies at these timepoints) were previously recruited to tissues. Consistent with this hypothesis, the major phenotypic families at these timepoints belonged to superfamily C of poorly-cytotoxic NK cells (**Figure 4**). In addition, this switch may also reflect the persistence of some poorly cytotoxic NK cells in the blood after vaccination, rather than a true increase in number or redistribution. For example, family 7

remained constant in number at D1PP but still became proportionally one the most abundant families at this timepoint, because of the decrease in the numbers of the other NK cell populations (**Figure 5A** and **5B**).

Overall, this analysis demonstrated that the NK cell compartment was modified by the priming immunization, and the NK cell subphenotypes composition was not similar at HOPB relative to that at baseline. Strikingly, NK cells were mainly phenotypically highly cytotoxic at HOPB (phenotypic families 3 and 8), compared to HOPP samples where most NK cells were poorly/moderately cytotoxic (**Figure 4** and **Figure 5B**). Note that this phenotype modification occurred before the boosting immunization and is thus independent of the boost.

We finally analyzed the diversity and dynamics of the NK cell compartment using the Simpson index as a readout (**Figure 5C**). The wide diversity of the NK cell receptor repertoire, for which each combination of NK cell receptors can virtually give rise to a new subset of NK cells, was recently uncovered (5). However, the meaning of such NK cell diversity for vaccines is not yet understood. Admittedly, the lack of a larger set of inhibitory and activating NK receptors (which are difficult to analyze in NHP) in our antibody panel prevented us from directly addressing the issue of the NK cell repertoire, for which the diversity was previously shown to reflect immune experience (68). Nonetheless, we were able to observe two distinct and complex kinetic patterns among our four animals (BB078 and BB231 vs. BC641 and BD620), but by no means did we detect a progressive increase in NK cell subphenotype diversity over time and after immunization.

Altogether, the mass cytometry analysis revealed that the prime induced the modification of the NK cell subphenotype composition in two main steps, at D1PP and between D14PP and

the boost (D58PP). As a result of these phenotypic differences pre-existing prior to the boost, the NK cell response differed between prime and boost.

Key phenotypic signatures between the NK cell response to prime and boost

We then aimed to define the NK cell phenotypic families that discriminate the primary and secondary NK cell responses using an approach that combined LASSO and LDA methods.

We first used the LASSO method to determine the optimal number of phenotypic families that could account for post-prime and post-boost differences (**Figure S6**). Based on this analysis, we chose phenotypic families 3, 8, 7, 5, and 6 that were necessary and sufficiently informative to distinguish prime and boost samples through leave-one-out cross-validation (**Figure S6**).

These five phenotypic families were then used to build the LDA classification (**Figure 6A and 6B**). The classification of post-prime and post-boost samples was correct for 31 of 33 samples (94%) and showed that phenotypic families 5 and 7 were involved with the post-prime response, whereas phenotypic families 3, 6, and 8 were involved with the post-boost response.

We further determined the phenotypic differences that distinguished NK cells that responded to the prime from those responding to the boost. We examined the mean signal intensity (MSI) of prime-responding vs. boost-responding NK cells and identified eight markers that differed in expression intensity between the two signatures (**Figure 6C and 6D**): granzyme B, CD107a, perforin, CD69, CD66abce, CCR5, CD11c, and CD16. All were more highly expressed after the boost than the prime. To a lesser extent, CD11a was also more highly expressed after the boost than the prime (**Figure 6D**). This suggests that NK cells involved with the post-boost immune response showed a more cytotoxic phenotype (including the ability for antibody-

dependent cell cytotoxicity –ADCC– based on CD16 expression), associated with an increased ability to traffic to lymph nodes and inflamed tissues. Phenotypic family 5, which was involved in the post-prime response, also belonged to superfamily A of highly cytotoxic NK cells, together with phenotypic families 3 and 8 (**Figure 4**). However, it displayed a higher CCR5 expression and lower levels of CD2, CD7, CD16, and CD11a than the post-boost highly cytotoxic NK cells from phenotypic families 3 and 8, suggesting a stronger ability to traffic to inflamed tissues, while simultaneously showing a less mature/activated phenotype. This observation is consistent with the fact that NK cells responding to the boost showed a more cytotoxic (and potentially more mature) phenotype in the blood than those responding to the prime.

Validation of the phenotypic signature distinguishing NK responses to prime and boost

To validate the results and model obtained on samples from four animals, we used four samples from a fifth animal from the same cohort, macaque BD619, which was not included in the previous steps of the analysis. After associating each cell to the SPADE cluster it was the closest to, we were able to define the phenotypic composition of these samples with respect to our SPADE analysis (**Figure 7A**). BD619 showed a phenotypic signature fairly consistent with the four animals used to build the model, with a high abundance of phenotypic family 7 and 9 at H3PP, H6PP and D1PP, a high abundance of phenotypic families 2 and 4 at D1PP and D1PB, and high abundance of phenotypic family 3 at D1PB. We then applied the LDA classifier detailed in **Figure 6** on these new samples (**Figure 7B**). Three samples (H3PP, D1PP, and D1PB) out of four were correctly classified. Interestingly, the sole error made was on H6PP (which obtained a low post-boost score), the timepoint for which the model already misclassified the

BC641 sample. This misclassification is due to the relatively high abundance of family 8 at H6PP for these two animals, while family 8 is overall more enriched after the boost and was used as such in the LDA classifier.

In conclusion, applying our SPADE analysis and resulting LDA generated from “only” four animals (but 39 samples) on those previously unseen samples gave consistent results and strengthened the definition of our NK cell signature to prime and boost.

The NK cell response correlates with the innate myeloid response

We further investigated how the NK cell response integrated with the innate myeloid response to MVA. We previously reported, in the same animals, that neutrophils, monocytes, and cDCs responded differently to the priming and boosting immunization. Some subphenotypes were enriched only after one of the two immunizations, with cells responding to the boost expressing higher levels of markers involved in phagocytosis, antigen presentation, co-stimulation, chemotaxis, and inflammation (27). Here, we assessed the correlation between the dynamics of NK cell subphenotypes and those of these innate myeloid cell subphenotypes, based on cell abundance (**Figure 8**).

The abundance of NK cells responding to the prime inversely correlated ($R < -0.6$) with that of the innate myeloid cells responding to the boost, but did not correlate ($|R| < 0.6$) with that of innate myeloid cells responding to the prime. In contrast, the abundance of NK cells responding to the boost positively correlated ($R > 0.6$) with that of innate myeloid cells responding to the boost, but there was no association ($|R| < 0.6$) with that of innate myeloid cells responding to the prime. One explanation may be that the kinetics of NK cells and innate myeloid cells are not synchronous. Indeed, NK cell expansion mainly occurred at H3-H6 for the

592 post-prime expanded subphenotypes, whereas innate myeloid cells that expanded post-prime
593 were still numerous at D1. Conversely, innate myeloid cells that expanded post-boost mainly
594 expanded around H6, simultaneously with NK cells. This also indicates that innate myeloid and
595 NK cell responses are more synchronous during the response to the boost.

Discussion

We previously reported that vaccination elicits a distinct innate myeloid immunity between prime and after boost (27). Using the very same animals, we show here that, NK cell immune responses also differ between each immunization. In contrast to the myeloid response, blood NK cell dynamics were mainly driven by decreases in cell number and there was wider inter-individual variability. We have previously documented a transient decrease of NK cell numbers in the blood after intradermal MVA injection in macaques (46). In contrast to total NK cells, some NK cell subphenotypes increased in number after immunization, with some showing a differential enrichment after the prime and boost. More strikingly, our study revealed that some modifications of NK cell subphenotype composition towards a more mature and cytotoxic phenotype were induced by the prime. These changes occurred in two steps : a first early and quite long-lasting shift in phenotype (from D1PP and maintained up to D14PP), followed by a later one (between D14PP and D58PP). As a core result of these phenotypic changes, the NK cell composition before the prime and prior to the boost differed, and the NK cells responding to the boost were phenotypically more mature/cytotoxic.

There are numerous terminologies used in literature to described distinct NK cells subpopulations displaying memory-like features including but not limited to antigen-specific NK cells (17–19,69), cytokine-induced NK cells (18,19), cytokines activated NK cells (69), liver-restricted NK cells (19), memory-like NK cells (18) or adaptive NK cells (18). Many of these data were obtained in patients or animals infected by the cytomegalovirus. To our knowledge there is not yet a clear consensus on the phenotype of these different subpopulations of NK cells, although some markers seem to be important, such as Ly49H and KLRG1 in mice or NKG2C and CD57 in humans (19,69). Due to a lack of reactivity with fixed macaque cells of antibodies

targeting many of NK receptors (such as NKp80, NKp46, NKp30, and CD158a), as well as CD57, those markers could not be included in our analyses, and available antibodies could not distinguish between NKG2A and NKG2C in macaques. In the present study, the main argument for induction of memory-like NK cells is the emergence or preponderance of some particular NK subphenotypes and overall their persistence long after MVA prime (2 months). Whether these MVA prime induced NK cells correspond to memory-like NK cells, and which one (cytokine-induced or antigen-specific), remain to be fully tested with functional assays and transcriptional profiling approaches.

In addition, these missing markers may impair the capture of the whole NK cell diversity and explain why our LDA classifier was less efficient when dealing with NK cell subpopulation to distinguish post-prime and post-boost samples than the LDA generated on innate myeloid cells subpopulations (27), despite strong correlations between NK cell and innate myeloid cell response at the boost.

Besides, we noticed a high inter-individual variability in NK cell counts and phenotype at steady state, prior to any immunization, while this inter-individual variability was low after immunization, with all four animals behaving similarly. This indicated that changes induced by vaccination went beyond the sole inter-individual variability. In other words at baseline, without stimulation, the NK cells compartment activity is highly variable, whereas, upon stimulation (*e.g.*, immunization, very likely infection), this variability decreases. The number of animals ($n=4$) was not sufficient to address in details the variation in the phenotypic composition of the NK cell compartment prior to immunization. This would be a valuable problematic to tackle with, since this may explain some of the inter-individual differences in

term of immune responses observed in various contexts (such as infectious diseases and cancer).

Interestingly, the total NK cell dynamics were associated with the modulation of NK cell-related genes in PBMCs, in particular with the involvement of IL-12. However, the lack of available transcriptomic data at very early timepoints (such as H3, H6, and D1 post-immunization) prevented us from further assessing the kinetics of these transcripts during this period in which many dramatic changes in the abundance of NK cell phenotypic families occurred. In addition, transcript levels were assessed at the PBMC level, with NK cells potentially overwhelmed by B cells, T cells, and monocytes. Overall this transcriptomic dataset was rather a complementary piece of evidence to show that immunizations impacted NK cells as a cellular compartment. Future studies addressing vaccine-induced NK cell response should include early timepoints and use purified NK cells or even single cells, given the wide diversity of the NK cell repertoire. Still, interestingly, IL-12 has been described to be required in the efficient differentiation of both antigen-specific memory NK cells and cytokines activated NK cells in mice model after MCMV infection (69). Since we previously showed that IL-12 was upregulated in neutrophils in our vaccine schedule, we may hypothesize that IL-12 could play a similar role in the development of the phenotypically modified NK cells we observed here.

We used mass cytometry to identify key markers that clearly distinguish the NK cell immune response to the prime from that to the boost. Granzyme B, CD107a, perforin, CD69, CD66, CCR5, CD11c, CD16, and, to a lesser extent, CD11a were upregulated by NK cells responding to the boost. Several hypotheses can explain these prime-boost differences among NK cells, notably the presence of primary circulating antibodies that could activate NK cells via FcRs

(such as CD16), as well as the local immune reaction involving primary memory T cells and/or imprinting resident macrophages. But actually, these differences were induced by the prime and pre-existed to the boost.

CD107a, CD11a, CD11c, CD69, CD16, granzyme B, and perforin are associated with NK cell maturation and cytotoxic activity (53,54,70–72), suggesting that NK cells would be more cytotoxic after the boost than after the prime. The increase in CCR5 expression suggests that NK cells are more prone to recruitment to inflamed tissues, including the injection site or draining lymphoid organs (73,74). CD66 inhibits NKG2D signaling and subsequent cytotoxicity and may thus play a role in the downregulation of inflammation (65,75), consistent with the overall milder inflammation observed in the macaques at the boost relative to the prime (27). This suggests that prime-induced modifications of the NK cell compartment likely make it more effective in responding to subsequent infection/immunization, given its high activation potential. Whether direct ligand/receptor interactions between MVA and NK cells or cytokines play a role remains to be determined. Also, functional analyses are required to define the exact enhanced functions of the phenotypically distinct NK cells responding to the boost. Deep phenotyping analyses were performed on these animals on different cell compartments, not only in this paper but also elsewhere (27,37). As a consequence, the number of blood samples left available was too limited to assess NK cell functions at relevant timepoints.

Our results are in contrast to those obtained in mice, showing that MVA immunization, as opposed to vaccinia virus immunization, failed to induced memory-like NK cells after a single intraperitoneal injection (76). This strongly suggests that live, replication-competent micro-organisms are likely to be more efficient at priming innate immune memory. Several hypotheses could explain the discrepancies between these results in mice and ours, apart

687 from the simple difference between animal models. Indeed, different routes of injection may
688 differentially influence systemic immunity. For example, previous studies on trained immunity
689 showed that intravenous, but not subcutaneous, injection of BCG induced stem cells gave rise
690 to trained myeloid progeny (77). The impact that the route of injection could have on NK cell
691 responses is still largely unaddressed (21). Another explanation is that the authors focused on
692 the NK cell compartment six months after priming, without analyzing intermediate timepoints.
693 It is possible that the primed NK cells we observed in our setting may be only short-lived and
694 would vanish in the long-term in the absence of boosting.

695 Another question is whether those primed NK cells were antigen-specific (and in this case MVA
696 or HIV) or not. Indeed, one may wonder in which extent these phenotypically modified NK
697 cells provided cross-protection to a wide range of pathogens, as for trained innate myeloid
698 cells (78) or whether they would be restricted to some specific antigens (18). Indeed, should
699 they be antigen-specific, they would respond differently to the boost only if the correct
700 antigen is present in the boosting immunization. Should they be non-antigen-specific
701 (cytokine-induced memory NK cells), they would likely respond differently irrespectively of
702 the boost. Further functional studies will be required to firmly conclude on antigen specificity.

703 Strikingly, CD16, CCR5, and in a lesser extent CD11a, were more highly upregulated on NK cells
704 after the boost than the prime, similarly to monocytes, DCs, and neutrophils (27). This
705 indicates that (i) these features are shared by both lymphoid and myeloid innate cells and (ii)
706 one consequence of a boost is more consistent CCR5 upregulation, which is likely linked to
707 tissue recruitment. However, the innate myeloid and NK cell responses were clearly distinct,
708 with innate myeloid cells being rapidly enriched after immunization, whereas NK cell numbers
709 decreased. In addition, the kinetics of subphenotype composition modifications induced by

the prime differed between NK and innate myeloid cells. This suggests that the mechanisms behind the training of innate lymphoid and myeloid immune cells differ.

We found strong correlations between NK cell and innate myeloid cell responses. Responses to the boost clearly correlated between the two compartments. Similarly, the innate myeloid response to the boost negatively correlated with that of the NK cells to the prime. In contrast, the innate myeloid response to the prime did not correlate with that of the NK cells to the prime, neither did it negatively correlate with the NK cell response to the boost. Overall, this suggests that the innate response to the boost is more coordinated between NK cells and innate myeloid cells than the response to the prime. Whether this is the result of a more efficient crosstalk between NK cells and myeloid cells after the boost than after the prime is yet to be addressed.

Finally, addressing whether some features of the NK cell response correlate with the adaptive immune response and how this could be used to better predict the establishment of immune memory is still a challenge. Also, further investigating NK cell responses in tissues other than blood is another challenge that will need to be met to obtain a fully comprehensive picture of the vaccine-induced NK cell response.

To our knowledge, this is the first study using CyTOF technology for the longitudinal analysis of NK cells after vaccination. It revealed key features of NK cell phenotype after immunization and without any *ex vivo* re-stimulation with the vaccine in contrast to other studies analyzing the 'recall' NK cell response (8,79,80). This work aims to pave the way for future studies aiming to exploit this knowledge to optimize future vaccine.

Authorship

Conceptualization: RLG and ASB; immunization and blood sampling: NDB; cytometry: JLP, NT, NH, JEY, AC, MMT, and ASB; flow cytometry for MVA-buffer comparison: PR, FM, JLP, NT, and ASB; transcriptomics: JLP, NT, CL, HH, and ASB; writing of the original draft: JLP, NT, ASB; review and editing: NH, JEY, CL, PR, NDB, FM, HH, AC, MMT, YL, and RLG; acquisition of funding: YL, RLG, and ASB; supervision: RLG and ASB.

Acknowledgments

This work was supported by the “Investissements d’Avenir” programs managed by the ANR under reference ANR-10-LABX-77-01, funding the Vaccine Research Institute (VRI), Créteil (ImMemory research program), ANR-11-INBS-0008, funding the Infectious Disease Models and Innovative Therapies (IDMIT, Fontenay-aux-Roses, France) infrastructure, and ANR-10-EQPX-02-01, funding the FlowCyTech facility (IDMIT, Fontenay-aux-Roses, France), and by the European Union EVHA H2020 project (Grant N°681032). We would like to thank all members of the ASW and L2I groups from IDMIT as well as Romain Marlin. Nicolas Tchitchek held fellowships from the ANRS (France Recherche Nord&Sud Sida-HIV Hépatites).

Conflict of interest disclosure

The authors declare no conflict of interest.

753 **References**

- 754 1. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. *Science*
755 (2010) **327**:291–295. doi:10.1126/science.1183021
- 756 2. Artis D, Spits H. The biology of innate lymphoid cells. *Nature* (2015) **517**:293–301.
757 doi:10.1038/nature14189
- 758 3. Eberl G, Di Santo JP, Vivier E. The brave new world of innate lymphoid cells. *Nat Immunol* (2015)
759 **16**:1–5. doi:10.1038/ni.3059
- 760 4. Boudreau JE, Hsu KC. Natural Killer Cell Education and the Response to Infection and Cancer
761 Therapy: Stay Tuned. *Trends Immunol* (2018) **39**:222–239. doi:10.1016/j.it.2017.12.001
- 762 5. Wilk AJ, Blish CA. Diversification of human NK cells: Lessons from deep profiling. *J Leukoc Biol*
763 (2018) **103**:629–641. doi:10.1002/JLB.6RI0917-390R
- 764 6. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. *Nat Immunol*
765 (2008) **9**:503–510. doi:10.1038/ni1582
- 766 7. Pampena MB, Levy EM. Natural killer cells as helper cells in dendritic cell cancer vaccines. *Front*
767 *Immunol* (2015) **6**:13. doi:10.3389/fimmu.2015.00013
- 768 8. Horowitz A, Behrens RH, Okell L, Fooks AR, Riley EM. NK cells as effectors of acquired immune
769 responses: effector CD4+ T cell-dependent activation of NK cells following vaccination. *J Immunol*
770 (2010) **185**:2808–2818. doi:10.4049/jimmunol.1000844
- 771 9. Gao N, Jennings P, Yuan D. Requirements for the natural killer cell-mediated induction of IgG1
772 and IgG2a expression in B lymphocytes. *Int Immunol* (2008) **20**:645–657.
773 doi:10.1093/intimm/dxn021
- 774 10. Crouse J, Xu HC, Lang PA, Oxenius A. NK cells regulating T cell responses: mechanisms and
775 outcome. *Trends Immunol* (2015) **36**:49–58. doi:10.1016/j.it.2014.11.001
- 776 11. Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. *Trends*
777 *Immunol* (2004) **25**:47–52.
- 778 12. Van Elssen CHMJ, Oth T, Germeraad WTV, Bos GMJ, Vanderlocht J. Natural killer cells: the secret
779 weapon in dendritic cell vaccination strategies. *Clin Cancer Res* (2014) **20**:1095–1103.
780 doi:10.1158/1078-0432.CCR-13-2302
- 781 13. Rydzynski CE, Cranert SA, Zhou JQ, Xu H, Kleinstein SH, Singh H, Waggoner SN. Affinity Maturation
782 Is Impaired by Natural Killer Cell Suppression of Germinal Centers. *Cell Rep* (2018) **24**:3367-
783 3373.e4. doi:10.1016/j.celrep.2018.08.075
- 784 14. Vargas-Inchaustegui DA, Ying O, Demberg T, Robert-Guroff M. Evaluation of Functional NK Cell
785 Responses in Vaccinated and SIV-Infected Rhesus Macaques. *Front Immunol* (2016) **7**:340.
786 doi:10.3389/fimmu.2016.00340
- 787 15. Costanzo MC, Kim D, Creegan M, Lal KG, Ake JA, Currier JR, Streeck H, Robb ML, Michael NL,
788 Bolton DL, et al. Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1

789 infection and increased activity post-vaccination. *Nat Commun* (2018) **9**:1212.
790 doi:10.1038/s41467-018-03618-w

791 16. Sun JC, Ugolini S, Vivier E. Immunological memory within the innate immune system. *EMBO J*
792 (2014) **33**:1295–1303. doi:10.1002/embj.201387651

793 17. Reeves RK, Li H, Jost S, Blass E, Li H, Schafer JL, Varner V, Manickam C, Eslamizar L, Altfeld M, et
794 al. Antigen-specific NK cell memory in rhesus macaques. *Nat Immunol* (2015) **16**:927–932.
795 doi:10.1038/ni.3227

796 18. Paust S, Blish CA, Reeves RK. Redefining Memory: Building the Case for Adaptive NK Cells. *J Virol*
797 (2017) **91**: doi:10.1128/JVI.00169-17

798 19. Min-Oo G, Kamimura Y, Hendricks DW, Nabekura T, Lanier LL. Natural killer cells: walking three
799 paths down memory lane. *Trends Immunol* (2013) **34**:251–258. doi:10.1016/j.it.2013.02.005

800 20. Jost S, Altfeld M. Control of human viral infections by natural killer cells. *Annu Rev Immunol*
801 (2013) **31**:163–194. doi:10.1146/annurev-immunol-032712-100001

802 21. Rydyznski CE, Waggoner SN. Boosting vaccine efficacy the natural (killer) way. *Trends Immunol*
803 (2015) **36**:536–546. doi:10.1016/j.it.2015.07.004

804 22. Volz A, Sutter G. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current
805 Perspectives for Vaccine Development. *Adv Virus Res* (2017) **97**:187–243.
806 doi:10.1016/bs.aivir.2016.07.001

807 23. Milo I, Blecher-Gonen R, Barnett-Itzhaki Z, Bar-Ziv R, Tal O, Gurevich I, Feferman T, Drexler I, Amit
808 I, Bousso P, et al. The bone marrow is patrolled by NK cells that are primed and expand in
809 response to systemic viral activation. *Eur J Immunol* (2018) doi:10.1002/eji.201747378

810 24. Garcia Z, Lemaître F, van Rooijen N, Albert ML, Levy Y, Schwartz O, Bousso P. Subcapsular sinus
811 macrophages promote NK cell accumulation and activation in response to lymph-borne viral
812 particles. *Blood* (2012) **120**:4744–4750. doi:10.1182/blood-2012-02-408179

813 25. Moreno-Nieves UY, Didier C, Lévy Y, Barré-Sinoussi F, Scott-Algara D, ANRS HIV Vaccine Network
814 (AHVN). NK cells are primed by ANRS MVA(HIV)-infected DCs, via a mechanism involving NKG2D
815 and membrane-bound IL-15, to control HIV-1 infection in CD4+ T cells. *Eur J Immunol* (2014)
816 **44**:2370–2379. doi:10.1002/eji.201344149

817 26. Lehmann MH, Torres-Domínguez LE, Price PJR, Brandmüller C, Kirschning CJ, Sutter G. CCL2
818 expression is mediated by type I IFN receptor and recruits NK and T cells to the lung during MVA
819 infection. *J Leukoc Biol* (2016) **99**:1057–1064. doi:10.1189/jlb.4MA0815-376RR

820 27. Palgen J-L, Tchitchek N, Elh mouzi-Younes J, Delandre S, Namet I, Rosenbaum P, Dereuddre-
821 Bosquet N, Martinon F, Cosma A, Lévy Y, et al. Prime and Boost Vaccination Elicit a Distinct Innate
822 Myeloid Cell Immune Response. *Sci Rep* (2018) **8**:3087. doi:10.1038/s41598-018-21222-2

823 28. Hong HS, Rajakumar PA, Billingsley JM, Reeves RK, Johnson RP. No monkey business: why
824 studying NK cells in non-human primates pays off. *Front Immunol* (2013) **4**:32.
825 doi:10.3389/fimmu.2013.00032

826 29. Davies DH, Wyatt LS, Newman FK, Earl PL, Chun S, Hernandez JE, Molina DM, Hirst S, Moss B,
827 Frey SE, et al. Antibody profiling by proteome microarray reveals the immunogenicity of the

828 attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. *J*
829 *Virol* (2008) **82**:652–663. doi:10.1128/JVI.01706-07

830 30. Carter DL, Shieh TM, Blosser RL, Chadwick KR, Margolick JB, Hildreth JE, Clements JE, Zink MC.
831 CD56 identifies monocytes and not natural killer cells in rhesus macaques. *Cytometry* (1999)
832 **37**:41–50.

833 31. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, Moretta L, Moretta A. p46, a
834 novel natural killer cell-specific surface molecule that mediates cell activation. *J Exp Med* (1997)
835 **186**:1129–1136.

836 32. Huot N, Jacquelin B, Garcia-Tellez T, Rasclé P, Ploquin MJ, Madec Y, Reeves RK, Derreudre-
837 Bosquet N, Müller-Trutwin M. Natural killer cells migrate into and control simian
838 immunodeficiency virus replication in lymph node follicles in African green monkeys. *Nat Med*
839 (2017) **23**:1277–1286. doi:10.1038/nm.4421

840 33. Vargas-Inchaustegui DA, Helmold Hait S, Chung HK, Narola J, Hoang T, Robert-Guroff M.
841 Phenotypic and Functional Characterization of Circulatory, Splenic, and Hepatic NK Cells in Simian
842 Immunodeficiency Virus-Controlling Macaques. *J Immunol* (2017) **199**:3202–3211.
843 doi:10.4049/jimmunol.1700586

844 34. Webster RL, Johnson RP. Delineation of multiple subpopulations of natural killer cells in rhesus
845 macaques. *Immunology* (2005) **115**:206–214. doi:10.1111/j.1365-2567.2005.02147.x

846 35. Reeves RK, Evans TI, Gillis J, Johnson RP. Simian immunodeficiency virus infection induces
847 expansion of alpha4beta7+ and cytotoxic CD56+ NK cells. *J Virol* (2010) **84**:8959–8963.
848 doi:10.1128/JVI.01126-10

849 36. Brandler S, Lepelley A, Desdouits M, Guivel-Benhassine F, Ceccaldi P-E, Lévy Y, Schwartz O, Moris
850 A. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen
851 presentation and antiviral effect. *J Virol* (2010) **84**:5314–5328. doi:10.1128/JVI.02329-09

852 37. Pejoski D, Tchitchek N, Rodriguez Pozo A, Elhmouzi-Younes J, Yousfi-Bogniaho R, Rogez-Kreuz C,
853 Clayette P, Dereuddre-Bosquet N, Lévy Y, Cosma A, et al. Identification of Vaccine-Altered
854 Circulating B Cell Phenotypes Using Mass Cytometry and a Two-Step Clustering Analysis. *J*
855 *Immunol* (2016) **196**:4814–4831. doi:10.4049/jimmunol.1502005

856 38. Egger G, Burda A, Glasner A. A simple method for measuring the F-actin content of human
857 polymorphonuclear leukocytes in whole blood. *Virchows Arch* (2001) **438**:394–397.

858 39. Elhmouzi-Younes J, Palgen J-L, Tchitchek N, Delandre S, Namet I, Bodinham CL, Pizzoferro K, Lewis
859 DJM, Le Grand R, Cosma A, et al. In depth comparative phenotyping of blood innate myeloid
860 leukocytes from healthy humans and macaques using mass cytometry. *Cytometry A* (2017)
861 doi:10.1002/cyto.a.23107

862 40. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, Moretta L. Human
863 NK cell receptors/markers: a tool to analyze NK cell development, subsets and function.
864 *Cytometry A* (2013) **83**:702–713. doi:10.1002/cyto.a.22302

865 41. Finck R, Simonds EF, Jager A, Krishnaswamy S, Sachs K, Fantl W, Pe'er D, Nolan GP, Bendall SC.
866 Normalization of mass cytometry data with bead standards. *Cytometry A* (2013) **83**:483–494.
867 doi:10.1002/cyto.a.22271

- 868 42. Qiu P, Simonds EF, Bendall SC, Gibbs KD, Bruggner RV, Linderman MD, Sachs K, Nolan GP, Plevritis
869 SK. Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. *Nat*
870 *Biotechnol* (2011) **29**:886–891. doi:10.1038/nbt.1991
- 871 43. Gautreau G, Pejoski D, Le Grand R, Cosma A, Beignon A-S, Tchitchek N. SPADEVizR: an R package
872 for Visualization, Analysis and Integration of SPADE results. *Bioinformatics* (2016)
873 doi:10.1093/bioinformatics/btw708
- 874 44. Platon L, Pejoski D, Gautreau G, Targat B, Le Grand R, Beignon A-S, Tchitchek N. A computational
875 approach for phenotypic comparisons of cell populations in high-dimensional cytometry data.
876 *Methods* (2017) doi:10.1016/j.ymeth.2017.09.005
- 877 45. Marlin R, Nugeyre M-T, Tchitchek N, Parenti M, Hocini H, Benjelloun F, Cannou C, Dereuddre-
878 Bosquet N, Levy Y, Barré-Sinoussi F, et al. Modified Vaccinia Virus Ankara Vector Induces Specific
879 Cellular and Humoral Responses in the Female Reproductive Tract, the Main HIV Portal of Entry.
880 *J Immunol* (2017) **199**:1923–1932. doi:10.4049/jimmunol.1700320
- 881 46. Rosenbaum P, Tchitchek N, Joly C, Stimmer L, Hocini H, Dereuddre-Bosquet N, Beignon A-S,
882 Chapon C, Levy Y, Le Grand R, et al. Molecular and Cellular Dynamics in the Skin, the Lymph
883 Nodes, and the Blood of the Immune Response to Intradermal Injection of Modified Vaccinia
884 Ankara Vaccine. *Front Immunol* (2018) **9**: doi:10.3389/fimmu.2018.00870
- 885 47. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A,
886 Bork P, et al. The STRING database in 2017: quality-controlled protein-protein association
887 networks, made broadly accessible. *Nucleic Acids Res* (2017) **45**:D362–D368.
888 doi:10.1093/nar/gkw937
- 889 48. Spidlen J, Breuer K, Rosenberg C, Kotecha N, Brinkman RR. FlowRepository: a resource of
890 annotated flow cytometry datasets associated with peer-reviewed publications. *Cytometry A*
891 (2012) **81**:727–731. doi:10.1002/cyto.a.22106
- 892 49. Kolesnikov N, Hastings E, Keays M, Melnichuk O, Tang YA, Williams E, Dylag M, Kurbatova N,
893 Brandizi M, Burdett T, et al. ArrayExpress update--simplifying data submissions. *Nucleic Acids Res*
894 (2015) **43**:D1113–1116. doi:10.1093/nar/gku1057
- 895 50. Martinet L, Ferrari De Andrade L, Guillerey C, Lee JS, Liu J, Souza-Fonseca-Guimaraes F,
896 Hutchinson DS, Kolesnik TB, Nicholson SE, Huntington ND, et al. DNAM-1 expression marks an
897 alternative program of NK cell maturation. *Cell Rep* (2015) **11**:85–97.
898 doi:10.1016/j.celrep.2015.03.006
- 899 51. Biassoni R, Fogli M, Cantoni C, Costa P, Conte R, Koopman G, Cafaro A, Ensoli B, Moretta A,
900 Moretta L, et al. Molecular and functional characterization of NKG2D, NKp80, and NKG2C
901 triggering NK cell receptors in rhesus and cynomolgus macaques: monitoring of NK cell function
902 during simian HIV infection. *J Immunol* (2005) **174**:5695–5705.
- 903 52. Borrego F, Robertson MJ, Ritz J, Peña J, Solana R. CD69 is a stimulatory receptor for natural killer
904 cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. *Immunology* (1999) **97**:159–
905 165.
- 906 53. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. *Nat*
907 *Rev Immunol* (2002) **2**:735–747. doi:10.1038/nri911

54. Urlaub D, Höfer K, Müller M-L, Watzl C. LFA-1 Activation in NK Cells and Their Subsets: Influence of Receptors, Maturation, and Cytokine Stimulation. *J Immunol* (2017) **198**:1944–1951. doi:10.4049/jimmunol.1601004
55. Gao J-Q, Tsuda Y, Han M, Xu D-H, Kanagawa N, Hatanaka Y, Tani Y, Mizuguchi H, Tsutsumi Y, Mayumi T, et al. NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy. *Cancer Immunol Immunother* (2009) **58**:291–299. doi:10.1007/s00262-008-0554-x
56. Zwirner NW, Ziblat A. Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27. *Front Immunol* (2017) **8**: doi:10.3389/fimmu.2017.00025
57. Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. *J Immunol* (2004) **173**:3653–3659.
58. Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. *Cell Immunol* (2015) **294**:63–69. doi:10.1016/j.cellimm.2015.01.018
59. Brumbaugh KM, Binstadt BA, Billadeau DD, Schoon RA, Dick CJ, Ten RM, Leibson PJ. Functional Role for Syk Tyrosine Kinase in Natural Killer Cell-mediated Natural Cytotoxicity. *J Exp Med* (1997) **186**:1965–1974.
60. Cardone J, Le Friec G, Kemper C. CD46 in innate and adaptive immunity: an update. *Clin Exp Immunol* (2011) **164**:301–311. doi:10.1111/j.1365-2249.2011.04400.x
61. McNerney ME, Kumar V. The CD2 family of natural killer cell receptors. *Curr Top Microbiol Immunol* (2006) **298**:91–120.
62. Liu LL, Landskron J, Ask EH, Enqvist M, Sohlberg E, Traherne JA, Hammer Q, Goodridge JP, Larsson S, Jayaraman J, et al. Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans. *Cell Rep* (2016) **15**:1088–1099. doi:10.1016/j.celrep.2016.04.005
63. Rölle A, Halenius A, Ewen E-M, Cerwenka A, Hengel H, Momburg F. CD2-CD58 interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection. *Eur J Immunol* (2016) **46**:2420–2425. doi:10.1002/eji.201646492
64. Milush JM, Long BR, Snyder-Cappione JE, Cappione AJ, York VA, Ndhlovu LC, Lanier LL, Michaëlsson J, Nixon DF. Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. *Blood* (2009) **114**:4823–4831. doi:10.1182/blood-2009-04-216374
65. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L, et al. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. *J Immunol* (2002) **168**:2803–2810.
66. Pillarisetty VG, Katz SC, Bleier JI, Shah AB, Dematteo RP. Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. *J Immunol* (2005) **174**:2612–2618.
67. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. *J Immunol* (2004) **173**:3716–3724.

- 948 68. Strauss-Albee DM, Fukuyama J, Liang EC, Yao Y, Jarrell JA, Drake AL, Kinuthia J, Montgomery RR,
949 John-Stewart G, Holmes S, et al. Human NK cell repertoire diversity reflects immune experience
950 and correlates with viral susceptibility. *Sci Transl Med* (2015) **7**:297ra115.
951 doi:10.1126/scitranslmed.aac5722
- 952 69. Nabekura T, Lanier LL. Tracking the fate of antigen-specific versus cytokine-activated natural
953 killer cells after cytomegalovirus infection. *J Exp Med* (2016) **213**:2745–2758.
954 doi:10.1084/jem.20160726
- 955 70. Bruhns P, Jönsson F. Mouse and human FcR effector functions. *Immunol Rev* (2015) **268**:25–51.
956 doi:10.1111/imr.12350
- 957 71. Burt BM, Plitas G, Stableford JA, Nguyen HM, Bamboat ZM, Pillarisetty VG, DeMatteo RP. CD11c
958 identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis. *J*
959 *Leukoc Biol* (2008) **84**:1039–1046. doi:10.1189/jlb.0408256
- 960 72. Aranami T, Miyake S, Yamamura T. Differential expression of CD11c by peripheral blood NK cells
961 reflects temporal activity of multiple sclerosis. *J Immunol* (2006) **177**:5659–5667.
- 962 73. Khan IA, Thomas SY, Moretto MM, Lee FS, Islam SA, Combe C, Schwartzman JD, Luster AD. CCR5
963 is essential for NK cell trafficking and host survival following *Toxoplasma gondii* infection. *PLoS*
964 *Pathog* (2006) **2**:e49. doi:10.1371/journal.ppat.0020049
- 965 74. Weiss ID, Shoham H, Wald O, Wald H, Beider K, Abraham M, Barashi N, Galun E, Nagler A, Peled
966 A. Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under
967 physiological conditions. *Cytokine* (2011) **54**:249–257. doi:10.1016/j.cyto.2011.01.011
- 968 75. Mizrahi S'ar, Yefenof E, Gross M, Attal P, Ben Yaakov A, Goldman-Wohl D, Maly B, Stern N, Katz
969 G, Gazit R, et al. A phenotypic and functional characterization of NK cells in adenoids. *J Leukoc*
970 *Biol* (2007) **82**:1095–1105. doi:10.1189/jlb.0407205
- 971 76. Gillard GO, Bivas-Benita M, Hovav A-H, Grandpre LE, Panas MW, Seaman MS, Haynes BF, Letvin
972 NL. Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia
973 virus challenge in the absence of adaptive lymphocytes. *PLoS Pathog* (2011) **7**:e1002141.
974 doi:10.1371/journal.ppat.1002141
- 975 77. Kaufmann E, Sanz J, Dunn JL, Khan N, Mendonça LE, Pacis A, Tzelepis F, Pernet E, Dumaine A,
976 Grenier J-C, et al. BCG Educates Hematopoietic Stem Cells to Generate Protective Innate
977 Immunity against Tuberculosis. *Cell* (2018) **172**:176-190.e19. doi:10.1016/j.cell.2017.12.031
- 978 78. Netea MG, van der Meer JWM. Trained Immunity: An Ancient Way of Remembering. *Cell Host*
979 *Microbe* (2017) **21**:297–300. doi:10.1016/j.chom.2017.02.003
- 980 79. Long BR, Michaelsson J, Loo CP, Ballan WM, Vu B-AN, Hecht FM, Lanier LL, Chapman JM, Nixon
981 DF. Elevated frequency of gamma interferon-producing NK cells in healthy adults vaccinated
982 against influenza virus. *Clin Vaccine Immunol* (2008) **15**:120–130. doi:10.1128/CVI.00357-07
- 983 80. Darboe A, Danso E, Clarke E, Umesi A, Touray E, Wegmuller R, Moore SE, Riley EM, Goodier MR.
984 Enhancement of cytokine-driven NK cell IFN- γ production after vaccination of HCMV infected
985 Africans. *Eur J Immunol* (2017) **47**:1040–1050. doi:10.1002/eji.201746974

986

Figure legends

Figure 1. Experimental design and analysis strategy. The experimental approach, including (A) the vaccine schedule, (B) the 31-marker antibody panel, and (C) the analysis pipeline, is shown. Five cynomolgus macaques were subcutaneously immunized with MVA-HIV B vaccine (4.10^8 PFU) twice, two months apart. Blood samples were collected at the indicated timepoints, hours (H) or days (D), post-prime (PP), and post-boost (PB), for mass cytometry (blue dots) or transcriptomic experiments (green dots). FCS files retrieved from mass cytometry were entered into the SPADE algorithm after exclusion of background events, dead cells, and non-specifically stained putative eosinophils, to cluster leukocytes based on 25 clustering markers and identify NK cell clusters. NK cell clusters were further clustered into phenotypic families whose kinetics were analyzed. Prime vs. boost phenotypic signatures were eventually determined using the LASSO-LDA approach.

Figure 2. Identification of blood NK cells. (A) The generated SPADE tree is shown. This analysis was built using all samples from the dataset, except HOPP samples, which were later mapped onto the analysis. NK cell clusters ($CD3^- CD8^+$) are indicated in red. (B) The absolute number of total NK cells per individual animal at each timepoint is shown. Red arrows indicate MVA immunization. The mean AUC $\pm$ SD is indicated, as well as the p-value, after comparison by the permutation test and considered statistically significant when $p \leq 0.05$.

Figure 3. NK cell-associated transcriptomic signature. (A) Interactions among transcripts for which the expression correlated with NK cell abundance identified using the STRING database (47) ($|R| \geq 0.65$, $p\text{-value} \leq 0.05$). (B) Top five canonical pathways correlating with NK cell

abundance identified using IPA (Ingenuity Systems, Inc). (C) Top five upstream regulators correlating with NK cell abundance identified using IPA (Ingenuity Systems, Inc).

Figure 4. Phenotypic heatmap of NK cells. Each line of the heatmap corresponds to one cell cluster and each column to one marker. Marker expression is displayed according to phenotypical categorical bins, corresponding to the subdivision of marker range of expression in five categories between the 5th and 95th percentile of expression (the color code is indicated). The marker and cluster dendrograms are shown on the top and left, respectively. The cluster dendrogram defined phenotypic families and superfamilies. Phenotypic families were randomly numbered and colored with different shades of the same color for each superfamily. Markers used as SPADE clustering makers are shown in bold.

Figure 5. Different enrichment of NK cells after each immunization. (A) The individual abundance in the number of cells/ μ L of blood of each phenotypic family is shown over time. The mean AUC $\pm$ standard deviation and p-value (permutation test) are shown and the phenotypic families are grouped based on their profiles. (B) The composition of the phenotypic families is indicated over time for each timepoint and each animal. The size of the pie is proportional to the absolute count of total NK cells in the blood, as indicated. Pie slices correspond to phenotypic families and are color-coded as in **Fig. 4**. *na* stands for not available. (C) The inverse Simpson index, as a readout for diversity, is displayed for each animal over time. Each color represents a distinct animal.

Figure 6. Signature distinguishing the post-prime and post-boost NK cell response. LDA was performed after LASSO regression to select the combination of phenotypic families that best discriminate between post-prime (blue, phenotypic families 5 and 7) and post-boost (red, phenotypic families 6, 3, and 8) samples. Note that the baseline samples (HOPP and HOPB) were not used for this analysis. **(A)** LDA coefficients and **(B)** LDA scores for each sample are shown. **(C)** MSI histograms for the eight markers with the highest Kolmogorov Smirnov distance between phenotypic families that best discriminate between the post-prime (blue) and the post-boost (red) responses as defined in **(Fig. 6A)** are displayed based on the merge of all samples and all timepoints. **(D)** The Kolmogorov Smirnov distance of all markers, including the top eight markers with the highest distance (bright gray vs. dark gray) between phenotypic families that best discriminate between the post-prime and the post-boost responses are displayed.

Figure 7. Validation of the NK cell signature after immunization(s). Samples from macaque BD619 were mapped into the existing SPADE tree to **(A)** define the phenotypic composition of the NK cells compartment of these samples, and **(B)** assess the quality of the LDA model using new samples in the model generation.

Figure 8. Intercorrelation between NK cell and innate myeloid cell immune responses. Correlations between the abundance of NK and innate myeloid cell subphenotypes (27) were computed using the Spearman method. Correlations with $|R| \geq 0.6$ and $p \leq 0.05$ are represented by green ($R \geq 0.6$) and purple ($R \leq -0.6$) lines joining the indicated subphenotypes. LASSO/LDA was used to discriminate post-prime (blue) and post-boost (red) NK cell **(Fig. 6A)**

1055 and innate myeloid cell subphenotypes (27). Subphenotypes not necessary for the
1056 classification are shown in black.

1057

Cynomolgus macaque

MVA HIV B

NK cells phenotype

Poorly cytotoxic

Moderately cytotoxic

Highly cytotoxic

Prime vaccination

Baseline

Abundant NK cells Heterogeneously cytotoxic

Early time
post-prime

Rare NK cells

Moderately cytotoxic

2 months

Late time
post-prime

Abundant NK cells

Poorly cytotoxic

Boost vaccination

Right before
the boost

Abundant NK cells

Highly cytotoxic

Early time
post-boost

Rare NK cells

Highly cytotoxic

A

B

C

A

B

A

B

C

A

BB078
BB231
BC641
BD620

B

C

A

B

D

C

A

B

NK cells

Innate myeloid cells

prime signature ●

boost signature ●

not selected in LDA ●

positive correlation

negative correlation

Figure S1. NKG2A/C inter-individual variability of expression. The biplot of CD8 vs. NKG2A/C is displayed for each animal at steady state (D19 before the prime). Macaque BB078 showed a different NKG2A/C staining pattern.

Figure S2. Annotation of the SPADE tree. Representation of the SPADE tree structure overlaid with the MSI for each indicated marker used to manually annotated the SPADE tree and identified NK cells as CD3- CD8+ cells.

Figure S3. Specificity of vaccine-induced NK cell count decrease. (A) Variability of NK cell count across the three baselines. Dots from the same animal are linked together. (B) Evolution of NK cell count after buffer injection. (C) Evolution of NK cell number after MVA injection. (B-C) p-value: one-sample t-test on the changes of NK cell count compared to baseline for the three timepoints after immunization for all animals. (A-C) black: no injection, only anesthetic; blue: buffer; gold: MVA.

Figure S4. Peculiar NK cell clusters. Dotplots for NK cell clusters 502 and 892, each constituting its own phenotypic family, are displayed with the indicated markers, based on the merge of all samples (macaques and timepoints). They reveal the true coexpression of the indicated markers and not the co-existence of two cell population. Blue dotted line indicates density.

Figure S5. NK cells variability across baselines. (A) Absolute number of total NK cells is displayed for each of the two available baselines (D-19PP and H0PP) and for each animal. (B) The phenotypic family composition is given as well. The size of the pie is proportional to the absolute number of total NK cells. The inverse Simpson index, as a readout for diversity, is indicated below each pie.

A **B**

Figure S6. Selection of phenotypic families used for LDA classification using LASSO. (A) The evolution of LDA-LASSO coefficients at each step is represented for each phenotypic family. (B) The evolution of the mean standard error (MSE) at each step of the LASSO procedure, after leave-one-out cross-validation, is shown.

Metal	Marker	Clone	Surface	Intra-cellular
141Pr	CD66abce	TET2	●	
142Nd	HLA-DR	L243	●	
143Nd	CD3	SP34.2	●	
144Nd	CD107a	H4A3	●	
145Nd	CD8	RPAT8	●	
146Nd	CD45	D058-1283	●	
147Sm	IL-4	7A3-3		●
148Nd	Granzyme B	GB11		●
149Sm	CD56	NCAM16.2	●	
150Nd	CD62L	SK11	●	
152Sm	CD4	L200	●	
153Eu	CD11a	HI111	●	
154Sm	CD2	RPA2.10	●	
155Gd	CD7	M-T701	●	
156Gd	MIP-1 β	D21-1351		●
159Tb	TNF α	MAb11		●
160Gd	Ki-67	B56		●
161Dy	NKG2D	1D11	●	
162Dy	CD11c	3.9	●	
164Dy	CD69	FN50	●	
165Ho	IFN γ	B27		●
166Er	CD25	4e 3	●	
167Er	CD16	3G8	●	
168Er	CCR5	3A9	●	
169Tm	CXCR4	12G5	●	
170Er	CD14	M5E2	●	
171Yb	Perforin	Pf-344		●
172Yb	NKG2A/C ^a	Z199	●	
174Yb	CD20	2H7	●	
175Lu	CCR7	G043H7	●	
176Lu	IL-10	JES3-9D7		●

Table 1. Antibody panel. Targeted markers, clones, and metals are shown. The right columns indicate whether the staining was extra- or intra-cellular. ^aThe antibody clone Z199 recognizes both NKG2A and NKG2C.

	BB078	BB231	BC641	BD620
D-19PP	76,557	60,206	60,143	52,082
H0PP	74,607	93,135		67,358
H3PP	128,251	109,159	91,420	72,772
H6PP	124,104	161,898	128,497	66,482
D1PP	117,081	154,166	110,928	103,526
D3PP	79,789	81,863	76,958	
D14PP	116,972	108,706	124,386	86,044
H0PB	135,810	140,496		92,991
H3PB	179,476	208,479	61,579	
H6PB	177,204	222,968	196,870	118,859
D1PB	257,189	167,840	243,434	116,967
D3PB	72,879	130,925		95,656

Table 2. Cells acquired with the CyTOF. For each sample, the number of leukocytes detected by the CyTOF (after exclusion of double positive CD3⁺CD66⁺ eosinophils) is indicated. Not available samples are in grey.

Markers	Number of non-uniform NK cell clusters	Percentage of non-uniform NK cell clusters	ID of non-uniform NK cell clusters
CD2	4	12	582, 739, 788, 892
CD16	4	12	122, 380, 721, 788
Perforin	3	9	723, 757, 819
CD4	1	3	582
CD7	1	3	567
HLA-DR	1	3	567
NKG2A/C	1	3	892
CCR5	0	0	-
CCR7	0	0	-
CD3	0	0	-
CD8	0	0	-
CD11a	0	0	-
CD11c	0	0	-
CD14	0	0	-
CD20	0	0	-
CD25	0	0	-
CD45	0	0	-
CD66abce	0	0	-
CD62L	0	0	-
CD69	0	0	-
CD107a	0	0	-
CXCR4	0	0	-
Granzyme B	0	0	-
NKG2D	0	0	-

Table 3. Number and percentage of non-uniform NK cell clusters. The number, percentage, and ID of NK cell clusters that do not reach the condition of uniformity are shown.